The Regenerative Medicine (RM) Industry has been rapidly expanding in recent years, making it a high-value, fast-growth market. Key drivers for the market include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.
There are now accelerated pathways for advanced therapy medicinal products (ATMPs) in several countries worldwide, including the U.S., Japan, and South Korea. The legislation took effect in Japan in late 2014, in South Korea in 2016, and in the United States in 2017. Additionally, the EU has a program for product acceleration – Adaptive Pathways. These historic events demonstrate to investors, the public, and funding providers alike that regenerative medicine is a sector that has emerged, no longer one that is evolving in the future.
“Big Pharma” is also demonstrating a snowballing interest in regenerative medicine. At its core, this is a strategic way for pharmaceutical companies to diversify their product development pipeline. Much of this interest has been driven by progress with immunotherapy treatments, such as CAR-T cell therapies, most notably, Kymriah and Yescarta. After attaining FDA approvals, these two products achieved historic approvals across varied geographic markets, providing hope to millions of cancer patients worldwide.
The Regenerative Medicine (RM) Industry also saw venture capital investment expand from a mere $200 million in 2010 to a stunning $14.6 billion in 2018. This upsurge in venture capital investment represents growth of 7,300% over an eight-year period. The aggressive construction of cell and gene therapy manufacturing facilities is also being undertaken by biotech companies seeking their own production capabilities, as well as by CDMOs planning to serve third-party clients from across the RM sector. With more than 900+ brave companies composing the marketplace, regenerative medicine advances are truly disrupting healthcare.
The Regenerative Medicine (RM) Industry includes companies that are developing:
As the first and only market research firm to specialize in the stem cell industry, BioInformant has an exceptional and unique understanding of the Regenerative Medicine (RM) Industry. Founded in 2006, BioInformant has collected over 13 years of historical data on the RM industry, providing it with a robust historical database of data on which to make future market projections. Headquartered in Washington, DC, BioInformant is strategically positioned near industry lawmakers, the National Institutes of Health (N.I.H.), the U.S. FDA, and the Maryland Biotech Corridor, among other critical resources.
In addition to leveraging an experienced team of analysts, this experience provides BioInformant with access to Key Opinion Leaders (KOLs) from across the RM sector, including dozens of executives who were interviewed for this report. To date, BioInformant has interviewed leadership from FUJIFILM, Pluristem Therapeutics, Cynata Therapeutics, RooserBio, Celularity, Hemostemix, Glycostem, Accellta, ORIG3N, Gamida Cell, Nohla Therapeutics, Fortuna Fix, Avery Therapeutics, Stem Cell Medicine Ltd., Minerva Biotechnologies, Celyad, Universal Cells, Rhemastem, and hundreds of others. With research cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine, BioInformant serves Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs.
Claim this global strategic report to learn:
Table of Content
Statement of the Report
REGENERATIVE MEDICINE (RM): AN INTRODUCTION
A bird's Eye View of the RM Industry
Number of RM Companies
Table Number of RM Companies by Geography, 2018
Major Therapeutic Platforms and Enabling Technologies in RM Industry
Table Major Therapeutic Platforms and Enabling Technologies in RM Industry
RM Product Approvals in 2017/2018
Table RM Product Approvals in 2017/2018
Total RM Clinical Trials
Table Total RM Clinical Trials by Phase, 2017/2018
Total RM Clinical Trials by Technology Type
Table Total RM Clinical Trials by Technology Type
Patient Impact of Three U.S.-Approved RM Products, 2018
Table Patient Impact of Three RM Products, 2018
Select Anticipated RM Industry Clinical Trial Data Readouts: 2019
Table Select Anticipated RM Industry Clinical Trial Data Readouts: 2019
RM Industry-Total Global Financings: 2018
Table RM Industry-Total Global Financings, 2018
Total Financings to RM Industry by Type and Year, 2016-2018
Table Total Financings to RM Industry by Type and Year, 2016-2018
Corporate Partnerships (Upfront Payments) in RM Industry, 2018
Table Corporate Partnerships (Upfront Payments) in RM Industry, 2018
Private Placements and Venture Financings in RM Industry, 2018
Table Private Placements and Venture Financings in RM Industry, 2018
Public Offerings (IPOs & Follo-Ons) in RM Industry, 2018
Table Public Offerings (IPOs & Follow-Ons) in RM Industry, 2018
Total Merger & Acquisition within RM Industry by Year, 2016-2018
Table Total Merger & Acquisitions Within RM Industry by Year, 2015-2018
Market Access for Regenerative Medicines as of January 2019
Table Market Access for Regenerative Medicines as of January 2019
Anticipated RM Product Launches
Anticipated RM Treated Patient Numbers
Top 20 RM Companies by Pipeline Size
Table Top 20 RM Companies by Pipeline Size
RM Research Institutes
RM Research Institutes in the U.S.
Table RM Research Institutes in North America
RM Research Institutes in Europe
Table RM Research Institutes in Europe
RM Research Institutions in Australia
Table RM Research Institutes in Australia
University Research to Products in the Market
Table From University Research to Products in the Market
CELL THERAPY (CT): AN OVERVIEW
Cell Therapy Timeline
Table Timeline of Notable Events in Cell Therapy Sector
Types of Stem Cells Used in Cell Therapy
Hematopoietic Stem Cells (HSCs)
Table Common Indications for HSCT
Induced Pluripotent Stem Cells (iPSCs)
Table Leading iPS Cell Therapy Companies
Mesenchymal Stem Cells (MSCs)
Table MSC-Based Products with Marketing Approval (MA)
Neural Stem Cells (NSCs)
Table Select List of Companies Active in Clinical Trials using Neural Stem Cells
Indications Addressed by NSCs in Clinical Trials
Embryonic Stem Cells (ESCs)
Clinical Trials using Human Embryonic Stem Cells (hESCs)
Table Select Clinical Trials that Use hESCs
Number of Clinical Trials using hESC-Derived Cells in 2018
Table The 29 Clinical Trials using hESCs, 2018
Notable Events in Cell Therapy Space in 2018
Table Select Events in Cell Therapy Sector, 2018
Top 15 Cell Therapy Companies
Table Top 15 Cell and Gene Therapy Biotechs to Watch
GENE-MODIFIED CELL THERAPY & IMMUNOTHERAPIES
Number of Companies Developing Gene-Modified Cell Therapy Products
Table Number of Companies Developing Gene-Modified Cell Therapy Products
CAR-T Cell Therapy
Global Distribution of CAR-T Cell Therapy Companies
Table Geographical Distribution of CAR-T Cell Therapy Companies
Select Events in Cell-Based Immuno-Onclogy Space, 2018
Table Select Events in Cell-Based Immuno-Onclogy Space, 2018
T-Cell Receptor (TCR) Therapy
Table Examples of Clinical Trials Involving T-Cell Receptors (TCRs)
Natural Killer (NK) Cell Therapies
Table Select NK Cell Therapies in Clinical and Preclinical Development for Cancer
Tumor Infiltrating Lymphocytes (TILs) Therapy
Table Examples of Clinical Trials using TILs
Marrow-Infiltrating Lymphocytes (MILs)
Gamma-Delta T-Cells Therapy
Big Biopharma's Interest in Gamma-Delta T-Cells Therapy
Table Known Gamma-Delta T-Cell Therapy Companies
Dendritic Cell (DC) Therapy
Cancer Types Targeted by Dendritic Cell Therapy Studies
Ongoing Clinical Trials Testing DC Vaccines
Table Select Ongoing Clinical Trials Testing DC Vaccines
Gene Augmentation Therapy
Gene Inhibition Therapy
Suicide Gene Therapy
The Process of DNA Transfer in Gene Therapy
Ex vivo vs. in vivo Gene Therapies
Table Approved Gene Therapy Products (ex vivo and in vivo)
Ex vivo Gene Therapy
In vivo Gene Therapy
Autologous vs. Allogeneic Gene Therapies in Development
Number of Gene Therapy Companies in the World
Table Number of Gene and Gene-Based Medicine Companies by Geography
Gene Therapy Pipeline Volumes, 1995-2018
Big Pharma and Gene Therapy Development
Number of Gene Therapy Products Predicted to be Approved in Next Three Years
Gene Therapy Product Candidates Granted RMAT Designation
Table Gene Therapy Product Candidates Granted RMAT Designation, 2018
Gene Therapy Companies Active in Neurodegenerative Disorders (ND)
Table Gene Therapy Companies Active in ND by Region, 2018
Gene Therapy Developers for Neurodegenerative Diseases
Table Gene Therapy Developers for Neurodegenerative Disorders, 2018
Neurodegenerative Disorders Addressed by Gene Therapy Studies
Table Neurodegenerative Disorders Addressed by Gene Therapy Studies
Anticipated Events in Neurodegenerative Disease Space of Gene Therapy
Table Select Anticipated Events in ND Space of Gene Therapy, 2018
Important Events in Gene Therapy Space in 2018
Table Select Events in Gene Therapy and Genome Editing Space, 2017/2018
Leading Gene Therapy Startups
Table Leading Gene Therapy Startups
Smart Biomaterials in TE
3D Printable Inks
Synthetic and Naturally-Derived Scaffolds
Table Approved TE Products
Two Key Developments in Tissue Engineering Space in 2018
Table Select Events in Tissue Engineering Sector, 2018
GENE DELIVERY VEHICLES
Physical Properties of Commonly used Viral Vectors
Table Physical Properties of Commonly used Viral Vectors
Table Retroviruses: A Snapshot
Table Adenoviruses: A Snapshot
Herpes Simplex Viral Vectors
Table Herpes Simplex Viruses (HSV): A Snapshot
Lentivirus Vectors (LV)
Table Lentiviruses: A Snapshot
Adeno-Associated Virus Vectors
Table Adeno-Associated Viruses: A Snapshot
Table Genes Transduced by AAV for Specific Diseases
Table Dominating Viral Vectors in Gene Therapy Drug Development
Table Microinjection Method of Gene Delivery
Table Particle Bombardment Method of Gene Delivery
Table Laser Irradiation Method of Gene Delivery
Table Electroporation Method of Gene Delivery
Table Magnetofection Method of Gene Delivery
Table Sonoporation Method of Gene Delivery
RM: CLINICAL TRIAL LANDSCAPE
Table Number of Clinical Trials in RM Sector, 2017-2018
Number of People Participating in RM Clinical Trials
Table Number of Patient Participation in RM Clinical Trials, 2018
Clinical Trials by Therapeutic Category in the RM Sector, 2018
Table Clinical Trials by Therapeutic Category in the RM Sector, 2018
Cell Therapy Clinical Trials
Table Number of Cell Therapy Clinical Trials, 2017-2018
Cell Therapy Clinical Trials by Indication
Mesenchymal Stem Cells in Clinical Trials
Table Number of Clinical Trials using MSCs
Anticipated Clinical Events in Cell Therapy Space
Table Select Anticipated Clinical Data and Events in Cell Therapy Space
Clinical Trials in Gene-Modified Cell Therapies Space
Table Number of Gene-Modified Cell Therapy Clinical Trials, 2017-2018
Most Popular Target Antigens for CAR-T Cell Therapies
Antigens other Than CD19 in Clinical Trials Targeted by CAR-T
Table Antigens other Than CD19 in Clinical Trials Targeted by CAR-T
Antigens Targeted by CAR-T in Solid Cancers in Clinical Trials
Anticipated Developments in CAR-T Space
Table Select Anticipated Clinical Data and Events in CAR-T Cell Therapy Sector
Number of Gene Therapy Clinical Trials
Table Number of Gene Therapy Clinical Trials, 2017-2018
Therapy Clinical Trials by Geography
Table Gene Therapy Clinical Trials by Geography
Diseases Targeted by Gene Therapy
Table Diseases Targeted by Gene Therapy, 2018
Gene Types Transduced in Clinical Trials
Table Gene Types Transduced in Clinical Trials, 2018
Vectors used in Gene Therapy Clinical Trials
Table Vectors used in Gene Therapy Clinical Trials, 2018
Gene Therapy Clinical Trials for Neurodegenerative Indications by Type
Table Gene Therapy Clinical Trials for Neurodegenerative Indications by Type, 2018
Domination of Oncology in Gene Therapy Drug Development
Table Domination of Oncology in Gene Therapy Drug Development
Dominance of Viral Vectors in Gene Therapy
Gene Therapy Alliances Volume and Value, 2012-2018
Table Gene Therapy Alliances Volume and Value, 2012-2018
Anticipated Clinical Events in Gene Therapy Space, 2019/2020
Table Select Anticipated Clinical Data and Events in Gene Therapy Sector
Number of Tissue Engineering Clinical Trials
Table Number of Clinical Trials in TE Space, 2017-2018
Anticipated Clinical Events in Tissue Engineering Space
Table Select Anticipated Clinical Data and Events in Tissue Engineering Space
APPROVED RM PRODUCTS WORLDWIDE
Number of RM Products Approved by Geography
Table RM Products with MA by Region/Country
Approval of RM Products by Year
Table RM Products with MA Worldwide by Year
Number of Approved RM Products by Type
Table RM Products with MA Worldwide by Product Type, 2018
RM Products with MA Worldwide by Therapy Type
Table RM Products with MA Worldwide by Therapy Type, 2018
Indications Addressed by the Approved RM Products
Table Number of RM Products with MA Worldwide by Indication, 2018
Approved RM Products in Australia
Table Cell Therapy Product with MA in Australia by TGA7
RM Products Approved in Canada
Table Cell Therapy and Gene Therapy Products with MA in Canada by Health Canada
Gene Therapy Product Approved in China
Table Gene Therapy Product with MA in China by CFDA8
Approved RM Products in Europe
Table RM Products with MA in Europe by EMA9
Yescarta (Axicabtagene ciloleucel)
Imlygic (Talimogene laherparepvec)
RM Products with Withdrawn Approvals in Europe
Table RM Products with MA Withdrawn in the E.U. by EMA
Approved RM Products in India
Table Cell Therapy Products with MA in India by DCGI10
RM Products Approved in Japan
Table Cell and Tissue Engineered Products with MA in Japan by PMDA11
TEMCELL HS Inj.
RM Products Approved in New Zealand
Table Cell Therapy Products with MA in New Zealand by MEDSAFE12
RM Products Approved in South Korea
Table RM Products with MA in South Korea by MFDS13
Approved RM Products in the U.S.
HPC, Cord Blood
Table RM Products with MA in the U.S. by FDA
Luxturna (voretigene neparvovec-rzyl)
Yescarta (axicabtagene ciloleucel)
HPC, Cord Blood (Bloodworks)
HPC, Cord Blood (LifeSouth Community Blood Centers)
HPC, Cord Blood (Clinimmune Labs)
U.S. RM Products with RMAT Designation
Table RM Products with RMAT14 Designation by FDA
Pricing of RM Products
Table Pricing of RM Products
RM Products Expected to be Approved in Late 2019 or 2020
Table The Five Forthcoming RM Products
MANUFACTURING OF CELLS FOR CELL AND GENE THERAPIES
Table Expenditure Categories in Cell Products Manufacturing
Cost of Manufacture
Table The Impact of Head Count on Labor Cost
Cost of Manufacture in a Partially-Automated Facility
Table Cost of Production in a Partially Automated Facility
Cost of Manufacture in a Fully-Automated Facility
Table Cost of Production in a Fully Automated Facility
Net Present Cost (NPC) of the Three Methods
In-House Gene Therapy Manufacturing Capabilities of Select Big and Mid Pharma
Table In-House Gene Therapy Manufacturing Capabilities of Select Big and Mid Pharma
External Gene Therapy Manufacturing by Big and Mid Pharma
Table External Gene Therapy Manufacturing by Big and Mid Pharma
Cell and Gene Therapy Manufacturing Capacities in North America
Table Cell and Gene Therapy Manufacturing Capacities in North America
Cell and Gene Therapy Manufacturing Capacities in Europe
Table Cell and Gene Therapy Manufacturing Capacities in Europe
CDMOs & CDMOs
Table Select CDMOs in Cell and Gene Therapy Sector
Appropriate Phase for Outsourcing
Table The Appropriate Phase for Outsourcing a Cell or Gene Therapy Project
Important Points Condirered while Fixing a CMO/CDMO
Table Important Points Considered While Fixing a CDMO
In-House vs. Outsourcing
Table Share of In-House and CDMO Manufacture of Cell and Gene Therapies
Number of Cell Gene Therapy CMOs/CDMOs in Europe
Projected Growth of CMOs and CDMOs
Projected Growth of Cell Manufacturing Capacity
Global Market for RM Products
Table Global Market for RM Products by Therapy Type, 2018-2025
Global RM Products Market by Geography
Table Global Market for RM Products by Geography, 2018-2025
Global Market for Cell Therapy Products
Table Global Market for Approved Cell Therapy Products, 2018-2025
Global Market for Gene Therapy Products
Table Global Market for Gene Therapy Products, 2018-2025
Competitive Landscape in Gene-Modified Cell Therapy Products
Table Competitive Landscape in Gene-Modified Cell Therapy Products
Global Market for Viral Vector and Plasmid DNA Manufacturing
Table Vector and Plasmid DNA Manufacturing Market by Geography, 2018-2025
Global Market for Tissue-Engineered Products
Table Global Market for Tissue-Engineered Products, 2018-2025
4D Molecular Therapeutics, LLC
Table 4D Molecular Therapeutics' Product Pipeline
Abeona Therapeutics, Inc.
Table Abeona Therapeutics' Product Pipeline
Adaptimmune Therapeutics plc
Table Adaptimmune's Pipeline Programs
Advanced Bioscience Laboratories, Inc.
Aseptic Filling Services
Immunology and Biomarker Testing
Contract Research Assays
Clinical Immunology Solutions
In vivo and ex vivo Preclinical Studies
Product Development Solutions
Translational Product Development
Adverum Biotechnologies, Inc.
Allogene Therapeutics, Inc.
Table Allogene Therapeutics' Pipeline of Allogeneic T-Cell Product Candidates
Amarna Therapeutics B.V.
Simian Virus 40 (SVac) Platform
Ambys Medicines, Inc.
American Gene Technologies International, Inc.
IMLYGIC (Talimogene laherparepvec)
Amicus Therapeutics, Inc.
Table Amicus' Gene Therapy Pipeline
Anterogen Co., Ltd.
APAC Biotech Pvt., Ltd.
apceth Biopharma GmbH
Table apceth's Pipeline Overview
AskBio/Asclepios Biopharmaceutical, Inc.
Table AskBio's Therapeutic Pipeline
Asterias Biotherapeutics, Inc.
Table Asterias' Pipeline Programs
Atara Biotherapeutics, Inc.
Table Atara's Pipeline of T-Cell Immunotherapy and CAR-T Product Candidates
Table Athersys' Clinical Programs using MultiStem
ATVIO Biotech Ltd.
Audentes Therapeutics, Inc.
AT132 for X-Linked Myotubular Myopathy
AT342 for Crigler-Najjar Syndrome
AT982 for Pompe Disease
AT307 for CASQ2-CPVT
Table Audentes' Product Candidates
Avita Medical Ltd.
AVR-RD-01 for Fabry Disease
AVR-RD-02 for Gaucher Disease
AVR-RD-03 for Pompe Disease
AVR-RD-04 for Cystinosis
Table AVROBIO's Gene Therapy Programs
Batavia Bioscience B.V.
Bellicum Pharmaceuticals, Inc.
Table Bellicum Pharmaceuticals' Product Candidates
Benitec Biopharma Limited
Table Benitec's Product Pipeline using Gene Silencing Technologies
Engineered Micro-Pancreas (EMP)
Table BioCardia's Advanced Pipeline
Table Biomay's Pipeline of Products
Biosolution Co., Ltd.
Table Biosolution's Products and Product Candidates
Cellspan Esophageal Implants
Cellspan Bronchial Implants
Cellspan Tracheal Implants
Table Bioverativ's Product Pipeline
bluebird bio, Inc.
Table bluebird bio's Product Pipeline
Bone Therapeutics SA
Brainstorm Cell Therapeutics, Inc.
Table Brainstorm's Clinical Programs
Brammer Bio, LLC
Gene Therapy Manufacturing
Caladrius Biosciences, Inc.
Table Caladrius' Proprietary Technology Platforms and Pipeline Programs
CARsgen Therapeutics, Ltd.
Table CARsgen Therapeutics' Product Candidates
Table Casebia's Pipeline at-a-glance
Cell Cure Neurociences Ltd.
Cellerant Therapeutics, Inc.
Table Cellerant's Program Pipeline for Blood Disorders
Cell Medica Limited
Table Cell Medica's Product Pipeline
Cell Therapy Catapult, Ltd.
Cellular Biomedicine Group, Inc.
Table CBG's Immuno-Oncology Stem Cell Therapy Pipeline
Cellular Dynamics International, Inc.
Table Celyad's Programs' Status at a Glance
Cevec Pharmaceuticals GmbH
Cobra Biologics Ltd.
DNA Platform Process, Development and Scale Up
Viral Vector Platform Process
Table Corestem's Key Clinical Pharmaceutical Development
CRISPR Therapeutics AG
Table CRISPR Therapeutics' Clinical Programs
Table CureVac's RNA-Based Product Pipeline
Cynata Therapeutics, Ltd.
CytomX Therapeutics, Inc.
Table CytomX's Pipeline of Probody Therapeutics
Cytori Therapeutics, Inc.
Table Cytori's Cell Therapy Development Pipeline
Delphi Genetics S.A.
Dendreon Pharmaceuticals, Inc.
DNAlite Therapeutics, Inc.
Editas Medicine, Inc.
Table Editas' Diverse Product Pipeline
Elixirgen Therapeutics, LLC
Table Elixirgen's Pipeline for Genetic and Age-Related Diseases
Eureka Therapeutics, Inc.
Table Eureka's Development Pipeline
Fate Therapeautics, Inc.
Table Fate Therapeutics' Cell Therapy Product Candidates Pipeline
Fibrocell Technologies, Inc.
Table Fibrocell's Personalized Biologics Pipeline
FinVector Vision Therapies Oy
Freeline Therapeutics Ltd.
Table Freeline's Pipeline of Gene Therapy Treatments in Development
FUJIFILM Diosynth Biotechnologies, Inc.
Gamida Cell Ltd.
Table Gamida Cell's Pipeline Programs
Table Current Status of GC Cell's Clinical Activities
Gemini Therapeutics, Inc.
Table Gemini's Pipeline
Table Genethon's Products in Development
Generation Bio Co.
Glycostem Therapeutics BV
Table Hemostemix's Clinical Pipeline
Homology Medicines, Inc.
Gene Editing Platform
Table Horama's Product Pipeline
Immune Design Corporation
Table Immune Design's Product Pipeline
Innovative Cellular Therapeutics Co., Ltd.
Table ICT's Pipeline Programs
Intellia Therapeutics, Inc.
Table Intellia's In Vivo and Ex Vivo R&D Pipeline
Iovance Biotherapeutics, Inc.
Table Iovance's Clinical Pipeline
JCR Pharmaceuticals Co., Ltd.
TEMCELL HS Inj.
Table JCR's RM Products in Development
JW CreaGene Co., Ltd.
Kaneka Eurogentec S.A.
KBI Biopharma, Inc.
Kiadis Pharma N.V.
Kite Pharma, Inc.
Table Kite's CAR-T Pipeline
Kolon Lifescience, Inc.
Table Kolon's Gene Therapeutics in Development
Krystal Biotech, Inc.
Table Krystal Biotech' Pipeline Programs for Orphan Skin Disease
Viral Vector Services
Lion TCR Pte. Ltd.
Table Lion TCR's Product Candidates
Lonza Group Ltd.
Custom Development and Manufacturing
Magenta Therapeutics, Inc.
Table Magenta's Product Candidates
Table Medigene's Immunotherapy Pipeline Projects
MEDIPOST CO., Ltd.
MeiraGTx Holdings plc
Table MeiraGTX's Pipeline
Table Mesoblast's Advanced Product Candidates
Miromatrix Medical, Inc.
MolMed's Clinical Trial Programs
MolMed's GMP Solutions
Table MolMed's Product Candidates
Mustang Bio, Inc.
Table Mustang Bio's Product Pipeline
Myonexus Therapeutics, Inc.
Table Myonexus' Clinical Stage LGMD Gene Therapy Pipeline
Table NantKwest's Clinical Trials using Cryopreserved haNK Cells
Table NexImmune's Adoptive Cellular Therapy (ACT) Programs
Nightstar Therapeutics plc
Table Nightstar Therapeutics' Pipeline Programs
Table Neuralstem's Cell Therapy Programs
Nohla Therapeutics, Inc.
Table Nohla's Donor Cell Therapy Programs
Novasep Holding SAS
Biopharmaceutical Manufacturing Solutions
Noveome Biotherapeutics, Inc.
Table Noveome's Clinical Pipeline
Orchard Therapeutics plc
Table Orchard Therapeutics' Pipeline
Osiris Therapeutics, Inc.
Grafix PL PRIME
Orthofix Medical, Inc.
Oxford BioMedica plc
Oxford BioMedica's Partnering Activities
Table Oxford BioMedica's Proprietary Product Pipeline
Table Oxford BioMedica's Partnered Products
Table Oxford BioMedica's IP Enabled and Royalty Bearing Products
Oxford Genetics Ltd.
Scalable AAV Custom Solutions
Paragon Bioservices, Inc.
Pharmicell Co., Ltd.
Table Pharmicell's Clinical Trials for Commercialization
Pluristem Therapeutics, Inc.
Posedia Therapeutics, Inc.
Table Posedia's Product Pipeline
Precision BioSciences, Inc.
ARCUS Genome Editing Platform
Prevail Therapeutics, Inc.
PROMETHERA Biosciences S.A.
Table PROMETHERA's Product Pipeline
PTC Therapeutics, Inc.
Table PTC Therapeutics' Gene Therapy Programs for CNS Disorders
Regenerative Medical System (RMS)
Table REGENXBIO's Product Pipeline
Partnerships and Licensing
Table REGENXBIO's Partners & Licensees Pipeline
ReNeuron Group plc
Table ReNeuron's Program Pipeline
Renova Therapeutics, Inc.
Table Renova's Product Pipeline
Richter-Helm BioLogics GmbH & Co. KG.
Rocket Pharmaceuticals, Inc.
MSCs in different Formats
Plug & Play Systems
Rubius Therapeutics, Inc.
Table Rubius' Pipeline Programs
Sangamo Therapeutics, Inc.
Table Sangamo's Proprietary Programs
Table Sangamo's Proprietary Programs
Sarepta Therapeutics, Inc.
Table Sarepta's Huge Product Pipeline
SCM Lifesciences Co., Ltd.
Table SCM Lifesciences' Product Pipeline
Semma Therapeutics Inc.
Sentien Biotechnologies, Inc.
Table Sentien's SBI-101 Clinical Programs
Sibiono GeneTech Co., Ltd.
Sirion Biotech GmbH
Solid Biosciences, Inc.
SGT-001 (Microdystrophin Gene Transfer)
Spark Therapeutics, Inc.
Luxturna (voretigene neparvovec)
Spark Therapeutics' Pipeline
Table Spark Therapeutics' Pipeline
Stempeutics Research Pvt., Ltd.
Takara Bio, Inc.
Services and Support
The Cell and Gene Therapy Catapult
Catapult's Industrialization Team
Catapult's Manufacturing Center at Stevenage
Catapult's Regulatory Team
Translate Bio, Inc.
Table Translate Bio's Two Lead Product Candidates
Triumvira Immunologics USA, Inc.
Table Triumvira's Product Pipeline
CAR-Treg Transplantation (TX200)
CAR-Treg Multiple Sclerosis
Ultragenyx Pharmaceutical, Inc.
Table uniQure's Product Pipeline
Vertex Pharmaceuticals, Inc.
Table Vertex Pharmaceuticals' Product Candidates
Table ViaCyte's Product Pipeline
Table Vybion's Drug Pipeline
Voyager Therapeutics, Inc.
Table Voyager's Pipeline Programs
Services and Products
WindMIL Therapeutics, Inc.
Wuxi App Tec, Inc.
Xalud Therapeutics, Inc.
Make an enquiry before buying this Report
Please fill the enquiry form below.